BOSTON--(BUSINESS WIRE)--PhysIQ
and Vital
Connect, Inc. today announced an initiative to evaluate how
clinician visits to home, when coupled with advanced continuous patient
monitoring, can potentially replace hospitalizations for common medical
admissions. This pilot is taking place at Partners HealthCare Brigham
and Women’s Hospital (BWH) and being led by David Levine, MD MA, a
physician at BWH.

“We are in a very exciting era of medicine where
clinical-grade biosensors and analytics are capable of delivering
continuous physiological insight that was traditionally only available
in the hospital environment.”

The Partners HealthCare BWH Home Hospital pilot is the first of two
planned initiatives to evaluate how technology and home-based care
delivery can be leveraged to treat patients who would otherwise be
admitted to the hospital. As part of the randomized controlled trial,
patients diagnosed at the BWH Emergency Department with exacerbation of
heart failure, pneumonia, COPD, cellulitis, or complicated urinary tract
infection are provided with a state-of-the-art home monitoring solution
for continuous physiologic insight and daily clinician visits. The
technology solution includes the Vital Connect VitalPatch®
biosensor that will continuously stream patient vital signs to be
analyzed by, and viewable through, the physIQ Personalized Physiology
Analytics platform.

“The evolution of digital medicine makes us even more confident in the
home hospital model for our patients. The purpose of this study is to
show how we can deliver superior outcomes at a lower cost for patients
who otherwise would be hospitalized,” said Dr. David Levine, the study’s
principal investigator. “We are in a very exciting era of medicine where
clinical-grade biosensors and analytics are capable of delivering
continuous physiological insight that was traditionally only available
in the hospital environment.”

The first phase of the initiative began mid-September 2016 and involves
up to 60 patients, half of whom are receiving traditional in-hospital
treatment, whereas the other half are receiving treatment at home.
Following successful implementation this year, the pilot will scale up
to 500 patients in early 2017. The primary aim of the implementation is
to demonstrate reduction in hospitalization costs for the at-home
population, along with improvement in a series of outcome measures
including health-related quality of life, patient safety and quality,
and overall patient experience.

“It’s extremely gratifying to know that leading institutions like
Partners HealthCare and Brigham and Women’s Hospital are embracing the
transformational potential of digital medicine and we are thrilled to be
a part of this exciting initiative in collaboration with our partners at
Vital Connect,” said Gary Conkright, CEO of physIQ.

Dr. Nersi Nazari, CEO of Vital Connect added, “It’s been our mission
from day one to provide clinical-grade physiological data through an
FDA-cleared wearable biosensor. We see this initiative as proof of a new
era of medicine—one where transformational models of care delivery are
enabled by continuous ambulatory monitoring technology.”

About physIQ:

PhysIQ is
a company dedicated to enabling proactive care delivery models through
its proprietary, FDA-cleared Personalized Physiology Analytics
technology. PhysIQ is a proven, first-of-its-kind data analytics
platform designed to process multiple vital signs from wearable sensors
to create a personalized dynamic baseline for each individual. By
mapping vital sign relationships this way, physIQ’s analytics detect
subtle deviations that may be a precursor to disease exacerbation or
change in health. With applications in both healthcare and wellness,
physIQ is transforming continuous physiological data into insight for
providers, health systems, payers, and pharmaceutical companies. For
more information, please visit www.physiq.com.

About Vital Connect, Inc.:

Vital
Connect, Inc. is a leader in wearable biosensor technology for
wireless hospital and remote patient monitoring. Vital Connect leverages
extensive expertise in bioengineering, data analytics, chip design, and
mobile and cloud software, creating technology that supports
decision-making paradigms to achieve better health and economic
outcomes. The Vital Connect® platform is FDA-cleared, CE-marked and
Ninsho Certified. It includes the HealthPatch®MD biosensor
and in the US and Europe, the single-use VitalPatch® biosensor. Vital
Connect products are designed for use in a broad range of inpatient and
outpatient settings for hospital, post-discharge, and cardiac monitoring
solutions. For more information, please visit www.vitalconnect.com.